Market Overview

UPDATE: Canaccord Genuity Upgrades Intuitive Surgical; Sensitivity Analysis Suggests Upside

Share:
Related ISRG
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More
The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Surgical and Amazon.com (Zacks)

Canaccord Genuity upgraded Intuitive Surgical (NASDAQ: ISRG) from Hold to Buy and lowered the price target from $590.00 to $527.00.

Canaccord Genuity analyst Jason R. Mills commented, "Our valuation analysis for both scenarios uses 1) 1.5x P/E/G multiple (in line with mid/large cap med-tech comps), and 2) two-year EPS CAGR derived from the aforementioned scenarios. The “moderate” downside scenario generates a year-end '13 target of $517, while the “significant” downside scenario implies a $474 target. Averaging our previous target of $590 (based on current estimates) with these scenario-based targets gives us a mean year-end target of $527. With more than 10% upside potential to our new target (15% to be exact), we upgrade to a BUY rating."

Intuitive Surgical closed at $459.44 on Friday.

Latest Ratings for ISRG

DateFirmActionFromTo
Jul 2015Canaccord GenuityUpgradesBuy
Jul 2015BarclaysMaintainsOverweight
Jul 2015Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Upgrades Analyst Ratings

 

Related Articles (ISRG)

Get Benzinga's Newsletters